Historic Moment In Battle Against Covid-19: Pfizer-BioNTech Vaccine To Be Available For The UK Public From Next Week Covid-19 vaccine - representative image (Twitter)

The United Kingdom has authorised the use of Pfizer-BioNTech Covid-19 vaccine for the use of the general public and will be rolled out from next week, Moneycontol has reported.

“The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s COVID-19 vaccine for use, The vaccine will be made available across the UK from next week” the government said.

As a result of the emergency authorisation the United Kingdom becomes the first nation in the world to authorise the use of the Pfizer-BioNTech vaccine.

The UK has placed an order for doses which will cover 20 million of its population. Each recipient requires two doses which will be administered in a gap of three weeks.

Priority will be given to frontline health workers, nursing home residents and the elderly.

The mRNA-based Covid-19 vaccine jointly developed by Pfizer and BioNTech has shown that it can prevent a Covid-19 infection in 90 per cent of the cases.

The trials of this vaccine were conducted on 43,500 people in six countries without any safety issues. The report adds that a preliminary analysis has found that this vaccine can prevent over 90 per cent of the people from contracting Covid-19.

This vaccine involves injecting part of the SARS-Cov-2 virus's RNA into the human body, which in-turn prompts the human body to produce the Coronavirus spike protein. The immune system is then prompted to produce antibodies and activate T-cells to destroy the infected cells.

Thus subsequently if the human encounters Covid-19 the antibodies and T-cells are triggered to fight it.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber